Navigation Links
Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
Date:9/4/2009

STOCKHOLM, September 4 /PRNewswire/ -- Karolinska Development (publ) today announced that one of its portfolio companies, Dilafor AB, has concluded an extensive clinical study of its candidate drug, tafoxiparin, a new drug substance for the prevention of protracted labor during childbirth. The promising results of the Phase II trial bring the project closer to exit in line with Karolinska Development's business strategy.

Dilafor's candidate drug, tafoxiparin DF01 is one of 11 compounds within the Karolinska Development portfolio that are currently conducting clinical trials. The completion of the Dilafor study is an important milestone for Karolinska Development and exemplifies the company's ability to develop innovative ideas through to clinical proof of concept quickly and efficiently. In the case of Dilafor, tafoxiparin has taken just six years to go from research concept to its current stage.

Karolinska Development's portfolio consists of more than 40 life science companies. A unique business model, which gives portfolio companies access to a broad network of business, legal, regulatory and scientific expertise, means that development times and costs are reduced compared to traditional drug development programs. With seven compounds currently undergoing Phase II clinical trials and five in Phase I the portfolio has matured to the point that Karolinska Development is now actively seeking commercial partners for its most advanced projects.

Conny Bogentoft, CEO of Karolinska Development, said, "The completion of the Dilafor Phase II trial is an important step for Karolinska Development and we are extremely pleased that Dilafor has achieved some very positive results. At the same time, it also goes a long way towards validating our business model. We are now very much focused on finding commercial opportunities for Dilafor's tafoxiparin and for several of our other projects that are reachin
'/>"/>

SOURCE Karolinska Development AB PUBL
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Karolinska Development Strengthens its Management Team With the Appointment of Dr Carl Harald Janson
2. Karolinska Development Closes Fully Subscribed New Share Issue
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
5. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
6. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
7. Global Experts Explore Entire Spectrum of Aids Vaccine Development
8. Vical Names Andrew de Guttadauro Vice President, Corporate Development
9. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
10. SemBioSys updates Apo AI development program
11. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015 Research ... addition of the "Global Biosimilars Market, 2015 ... The Global Biosimilars Market, 2015 - 2025, ... growing biosimilars market. With the blockbuster biologics losing ... costs, biosimilars are being viewed as viable substitutes ...
(Date:7/29/2015)... CHICAGO , July 29, 2015  AmnioChor Inc., ... cell technology, is very pleased to announce that the ... has agreed to invest in their seed round ... OmniBank placental tissue storage capabilities. AmnioChor,s ... placenta, and the human stem cells living within those ...
(Date:7/29/2015)... -- Pfenex Inc. (NYSE MKT: PFNX) announced today that its ... Thursday, August 13, 2015, before the open of market.  ... a conference call to discuss the financial results and ... financial results and business update will be publicly distributed ... (US) or 1-412-542-4131 (international) and reference Pfenex to access ...
(Date:7/29/2015)... NJ (PRWEB) , ... July 29, 2015 , ... The ... approval of combination products , in particular, drug/device combinations. The current system received ... by the Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ...
Breaking Biology Technology:Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3
... of the Medical College of Wisconsin, UW-Medical School, the ... Milwaukee business television show, Avante's Leaders in the New ... , ,Dr. Jeffrey Smith, clinical assistant professor of medicine ... was joined by Mike Klein, founder and editorial director ...
... week from his position as director of the nonpartisan ... on the reasons for his ouster. , ,And while ... results of an audit of the bureaus performance as ... Speaker John Gard (R-Peshtigo) said the move was simple ...
... publicly traded biotech stocks continue to show strong growth, the ... the rest of the market is catching up). , ... growth of 42 percent versus the Nasdaq Composites growth of ... 12 percent. The Amex Biotech index matches the high growth ...
Cached Biology Technology:The Information Age of Healthcare - Leaders featured on local new economy show 2The Information Age of Healthcare - Leaders featured on local new economy show 3Wahl Mute on Firing from Legislative IT Bureau -- but politics could be to blame 2Midwest Public-Sector Biotech Continues to Sizzle 2
(Date:7/9/2015)...  Synaptics Inc. (NASDAQ: SYNA ), a leading developer ... report financial results for the fourth quarter and fiscal ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-455-2260 (conference ...
(Date:7/8/2015)... July 8, 2015 Summary Pancreatic cancer ... fourth most fatal, with a mortality rate of 10.9 ... of pancreatic cancer patients has highlighted a significant need ... not being met by the current market. A ... products with varying molecule types and mechanisms of action, ...
(Date:7/7/2015)... Research and Markets ... the "Capacitive Fingerprint Sensors Patent Landscape" ... date, fingerprint sensing technology is the most reliable ... well developed. This patent landscape focuses on fingerprint ... domain of capacitive fingerprint sensors is closely linked ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... emotions are experienced in the body. Emotions adjust ... the challenges detected in the environment. These sensations arising ... our emotional experiences. For example, anxiety may be experienced ... may trigger warm, pleasurable sensations all over the body. ...
... in vascular transplantation, but it remains unclear whether the stress ... study reported in the Neural Regeneration Research (Vol. ... 7 200 seconds was similar between the middle cerebral artery ... 18.7 kPa or 22.5 kPa. However, the strain increase at ...
... least 4C by 2100 and potentially more than 8C by ... new research published in Nature . Scientists found global ... estimates. , The research also appears to solve one of ... formation and whether this will have a positive or negative ...
Cached Biology News:Finnish research team reveals how emotions are mapped in the body 2Cloud mystery solved: Global temperatures to rise at least 4°C by 2100 2
... PULSin is an innovative reagent for ... the cytoplasm of living cells. Unlike DNA ... Reagent the amount and timing of exogenous ... lethal proteins can now be studied. ...
... observations of cell cultures under precise, controlled ... strain parameters in addition to a microscope ... chamber used by the ST-195 is compatible ... can be used with Nikon, Olympus, Leica, ...
... research and biologic production demands on cell ... confirming viable cell populations. Therefore, both cell ... be determined accurately and precisely. The new ... and cost effective means to perform the ...
... PowerPac Basic power supply are used for electrophoretic ... cell accommodates two 7.5 x 10 cm gels ... assembly, Bio-Ice cooling unit, buffer tank, lid with ... basic power supply, 100-120 and 220-240 V, provides ...
Biology Products: